Betrixaban (PRT054021): Pharmacology, dose selection and clinical studies

Future Cardiology

Volumn 10, Issue 1, 2014, Pages 43-52

  Chan, Noel C ^a,b   Hirsh, Jack ^a,c   Ginsberg, Jeffrey S ^a,c   Eikelboom, John W ^a,b,c  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

atrial fibrillation; betrixaban; direct factor Xa inhibitor; oral anticoagulant; thromboprophylaxis

Indexed keywords

APIXABAN; BETRIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; BLEEDING; CAROTID ARTERY INJURY; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VEIN THROMBOSIS; VENA CAVA THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ATRIAL FIBRILLATION; BENZAMIDES; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; PYRIDINES; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84891118494     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.98     Document Type: Review

References (27)

1. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), e152S-e184S (2012
2. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009
3. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011
4. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981-992 (2011
5. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 368(8), 699-708 (2013
6. Buller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366(14), 1287-1297 (2012
7. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361(24), 2342-2352 (2009
8. Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombozlysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160(4), 635-641 (2010
9. Zhang P, Huang W, Wang L et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)benzamido)-5- methoxybenz amide, ahighly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg. Med. Chem. Lett. 19(8), 2179-2185 (2009
10. Turpie AG, Bauer KA, Davidson BL et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb. Haemost. 101(1), 68-76 (2009
11. Connolly SJ, Eikelboom J, Dorian P et al. Betrixaban compared with warfarin in patients with atrial fibrillation: Results of a Phase 2, randomized, dose-ranging study (EXPLORE-Xa). Eur. Heart J. 34(20), 1498-1505 (2013
12. Abe K, Siu G, Edwards S et al. Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, apotent oral factor Xa inhibitor. Blood 108(11), A270-A270 (2006
13. Sinha U, Edwards ST, Wong PW et al. Antithrombotic activity of PRT54021, a potent oral direct factor Xa inhibitor, can be monitored using a novel prothrombinase inhibition bioassay. Blood 108(11), A272-A272 (2006
14. Morganroth J, Gretler DD, Hollenbach SJ, Lambing JL, Sinha U. Absence of QTc prolongation with betrixaban: A randomized, double-blind, placebo-and positive-controlled thorough ECG study. Expert Opin. Pharmacother. 14(1), 5-13 (2013
15. Hutchaleelaha A, Ye C, Song Y, Lorenz T, Gretler D, Lambing JL. Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes. Presented at: 54th American Soceity of Hematology Annual Meeting and Exposition. Atlanta, GA, USA, 8-11 December 2012 (Abstract 2266
16. Hull RD, Schellong SM, Tapson VF et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial. Ann. Intern. Med. 153(1), 8-18 (2010
17. Goldhaber SZ, Leizorovicz A, Kakkar AK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365(23), 2167-2177 (2011
18. Cohen AT, Spiro TE, Buller HR et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N. Engl. J. Med. 368(6), 513-523 (2013
19. Lu G, Deguzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19(4), 446-451 (2013
20. Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: A novel, oral, direct factor Xa inhibitor. Semin. Thromb. Hemost. 33(5), 515-523 (2007
21. Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -an oral, direct factor Xa inhibitor. J. Thromb. Haemost. 3(3), 514-521 (2005
22. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 37(5), 1056-1064 (2009
23. Wong PC, Crain EJ, Xin B et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 6(5), 820-829 (2008
24. Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J. Thromb. Thrombolysis 31(4), 478-492 (2011
25. Zhang D, He K, Raghavan N et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab. Dispos. 37(8), 1738-1748 (2009
26. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab. Dispos. 40(12), 2250-2255 (2012
27. Furugohri T, Isobe K, Honda Y et al. DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J. Thromb. Haemost. 6(9), 1542-1549 (2008